May
2018

Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage (TICH-2): an international randomised, placebo-controlled, phase 3 superiority trial.

Sprigg N, Flaherty K, Appleton JP, et al.
Lancet 2018;391:2107-2115.
NATA Rating :
Review by : B. H. Hunt
NATA Review

This paper shows that tranexamic acid given up to 8 hours after primary intracerebral haemorrhage reduced haematoma expansion and early death compared with placebo without affecting rates of arterial and venous thrombosis or the number of seizures. However, the primary outcome at 90 days showed no difference in clinical function.

First thoughts are: tranexamic acid is “safe” to use in intracranial haemorrhage, which is good news for CRASH-3 and other trials. Secondly, although there was a reduction in haematoma expansion, it did not translate into better function. We at best would only expect a marginal effect, so maybe a larger trial is needed?

Beverley J.Hunt, FRCP, FRCPath, MD
Professor of Thrombosis and Haemostasis, King’s College London
Consultant, Guy’s and St Thomas’ NHS Foundation Trust
London, UK

LOGIN

Lost your password? Please enter your username or email address. You will receive a link to create a new password via email.
Don't have an account ? Click here to register
We do not share your personal details with anyone.